Risk factors for early and late recurrence in hepatitis B-related hepatocellular carcinoma
- PMID: 19747749
- DOI: 10.1016/j.jhep.2009.07.009
Risk factors for early and late recurrence in hepatitis B-related hepatocellular carcinoma
Abstract
Background/aims: Hepatitis B virus (HBV) levels correlate with the development of hepatocellular carcinoma (HCC), but the role of viral load in HCC recurrence after tumor resection remains unclear. Herein we aimed to investigate the role of viral load in HCC recurrence following tumor resection.
Methods: From 1990 to 2002, 193 HBV-related HCC patients who underwent tumor resection in Taipei Veterans General Hospital were enrolled. Serum HBV DNA level and mutations were analyzed for association with early and late recurrence, together with other clinical variables.
Results: During a follow-up of 58.2+/-44 months, 134 patients had HCC recurrence. Multivariate analysis showed that multinodularity (Hazard ratio [HR], 95% confidence interval [CI]; 2.232, 1.021-4.878), macroscopic venous invasion (4.693, 1.645-13.391), AFP >20 ng/ml (3.891, 1.795-8.475), and cut margin <or= 1cm (3.333, 1.487-7.470) were correlated with early recurrence (within two years of operation) of HCC. In addition, multivariate analysis determined that Ishak hepatic inflammatory activity >6 (4.658, 1.970-11.017), multinodularity (3.266, 1.417-7.526), ICG-15 >10% (2.487, 1.095-5.650) and HBV DNA level >10(6) copies/ml (2.548, 1.040-6.240) were significantly associated with late recurrence (>two years after resection). Patients with high viral loads tended to have higher Ishak inflammatory (7.00+/-3.07 vs. 5.33+/-2.96, p=0.001) and fibrosis scores (4.17+/-2.01 vs. 3.20+/-2.41, p=0.007) than those with lower loads.
Conclusions: Tumor factors were associated with early HCC recurrence while high viral loads and hepatic inflammatory activity were associated with late recurrence. Pre- and post-operative antiviral and anti-inflammatory therapies may be crucial in reducing late recurrence.
Comment in
-
Risk of recurrence in hepatitis B-related hepatocellular carcinoma: impact of viral load in late recurrence.J Hepatol. 2009 Nov;51(5):842-4. doi: 10.1016/j.jhep.2009.08.003. Epub 2009 Sep 2. J Hepatol. 2009. PMID: 19748698 Review. No abstract available.
Similar articles
-
Recurrence of hepatitis B-related hepatocellular carcinoma is associated with high viral load at the time of resection.Am J Gastroenterol. 2008 Jul;103(7):1663-73. doi: 10.1111/j.1572-0241.2008.01872.x. Epub 2008 Jul 4. Am J Gastroenterol. 2008. PMID: 18616655
-
Negative hepatitis B envelope antigen predicts intrahepatic recurrence in hepatitis B virus-related hepatocellular carcinoma after ablation therapy.J Gastroenterol Hepatol. 2011 Nov;26(11):1638-45. doi: 10.1111/j.1440-1746.2011.06777.x. J Gastroenterol Hepatol. 2011. PMID: 22011297
-
HBV DNA and HBsAg levels as risk predictors of early and late recurrence after curative resection of HBV-related hepatocellular carcinoma.Ann Surg Oncol. 2014 Jul;21(7):2429-35. doi: 10.1245/s10434-014-3621-x. Epub 2014 Mar 12. Ann Surg Oncol. 2014. PMID: 24619495
-
Risk of recurrence in hepatitis B-related hepatocellular carcinoma: impact of viral load in late recurrence.J Hepatol. 2009 Nov;51(5):842-4. doi: 10.1016/j.jhep.2009.08.003. Epub 2009 Sep 2. J Hepatol. 2009. PMID: 19748698 Review. No abstract available.
-
Hepatocellular carcinoma and hepatitis B virus.Semin Liver Dis. 2006 May;26(2):153-61. doi: 10.1055/s-2006-939753. Semin Liver Dis. 2006. PMID: 16673293 Review.
Cited by
-
Postoperative adjuvant immunotherapy and molecular targeted therapy for patients of hepatocellular carcinoma with portal vein tumor thrombus after hepatectomy: a propensity score matching study.Front Surg. 2024 Aug 7;11:1387246. doi: 10.3389/fsurg.2024.1387246. eCollection 2024. Front Surg. 2024. PMID: 39170098 Free PMC article.
-
Adjuvant treatment strategy after curative resection for hepatocellular carcinoma.Front Med. 2021 Apr;15(2):155-169. doi: 10.1007/s11684-021-0848-3. Epub 2021 Mar 23. Front Med. 2021. PMID: 33754281 Review.
-
Advances in postoperative adjuvant therapy for primary liver cancer.World J Gastrointest Oncol. 2022 Sep 15;14(9):1604-1621. doi: 10.4251/wjgo.v14.i9.1604. World J Gastrointest Oncol. 2022. PMID: 36187393 Free PMC article. Review.
-
Short- and Long-Term Outcomes of Indocyanine Green Fluorescence Navigation- Versus Conventional-Laparoscopic Hepatectomy for Hepatocellular Carcinoma: A Propensity Score-Matched, Retrospective, Cohort Study.Ann Surg Oncol. 2023 Apr;30(4):1991-2002. doi: 10.1245/s10434-022-13027-5. Epub 2023 Jan 16. Ann Surg Oncol. 2023. PMID: 36645540 Free PMC article.
-
Clinical Features of Recurrence After Hepatic Resection for Early-Stage Hepatocellular Carcinoma and Long-Term Survival Outcomes of Patients with Recurrence: A Multi-institutional Analysis.Ann Surg Oncol. 2022 Feb 22. doi: 10.1245/s10434-022-11454-y. Online ahead of print. Ann Surg Oncol. 2022. PMID: 35192156
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical